Piper Sandler Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $33

Benzinga Newsdesk www.benzinga.com Positive 86.9%

Neg 0% Neu 0% Pos 86.9%

Piper Sandler analyst Matt O'Brien upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Overweight and raises the price target from $21 to $33.